ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO990

Micral-Test® Strip to Detect Albuminuria Among Patients with CKD Risk Factors

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Ooi, Xi Yan, Tan Tock Seng Hospital, Singapore, Singapore
  • Weng, Wanting, Tan Tock Seng Hospital, Singapore, Singapore
  • Yeo, See Cheng, Tan Tock Seng Hospital, Singapore, Singapore

CKD is often asymptomatic and remains undiagnosed in its early stages. Screening and early identification of CKD allows implementation of treatment to delay progression and prevent adverse outcomes. To improve screening uptake and decrease screening cost in primary care,we piloted a 2 stage-screening strategy:pre-screening using microalbuminuria (Micral-Test®) strips, and confirmatory laboratory testing for positive results. In this study, we examined the testing characteristics of this screening strategy.


We provided Micral-Test® strips to 15 General Practitioners in Singapore. Individuals with these risk factors were offered screening:diabetes mellitus(DM), hypertension(HT), BMI>27.5kg/m2, age>60 years, cardiovascular/cerebrovascular disease, family history of kidney disease or smoking history. Patients with positive test were offered a specialist review for confirmation of albuminuria. We calculated a minimum sample size of 97 is needed to achieve 10% margin error and 95% confidence interval.


209 patients were recruited between April 2022 to April 2023; 72% had HT and 23% had DM. 111(53%) were screen positive and 43% of screen-positive subjects did not follow up with confirmatory testing. Of the 63 patients who proceeded with a confirmatory urine albumin-creatinine ratio test, 37(58.7%) had confirmed albuminuria; 29 moderately increased albuminuria and 8 severely increased albuminuria. The positive predictive value (PPV) of Micral-test was highest in patients with DM, with or without other comorbidities, and is relatively low in patients without any comorbidities(age>60 years only).


Majority of patients with risk factors for CKD have undiagnosed albuminuria. Our study suggests that Micral-test® strip can be used as an effective screening tool for albuminuria especially in patients with DM. There remains a large proportion of patients with screen positive results that declined further follow-up; further education and screening strategy should target this group for better CKD identification.

Test characteristics in different subpopulations
PopulationScreen positive(%)PPV(%)
Diabetes Mellitus77.680.8
Diabetes mellitus, hypertension and age>60 years old74.177.8
Age>60 years old only33.30


  • Commercial Support – AstraZeneca